Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MepAnti

Financiado

Cerrado

Exploiting the methylerythritol phosphate pathway as a source of drug targets fo...

Exploiting the methylerythritol phosphate pathway as a source of drug targets for novel anti infectives Anti-infective resistance is a serious global healthcare issue, calling for the development of compounds with a novel mode of action. An interdisciplinary approach will afford potent and selective inhibitors of the underexplored m... ver más

30/09/2024

HZI

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 11 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2024-09-30

MSCA-ITN-2019: Innovative Training Networks

I+D

Cerrada hace 6 años

0% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

11 Participantes

HZI

758.37K€ | Lider

HVL

292.34K€ | Participante

SPECS

265.62K€ | Participante

UGent

256.32K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

NovAnI Indentification and optimisation of novel anti infective age... 1M€ Cerrado

Mtb CoaBC CoaBC from the Coenzyme A pathway of Mycobacterium tuberculo... 183K€ Cerrado

NABATIVI Novel Approaches to Bacterial Target Identification Validat... 7M€ Cerrado

NovInDXS Development of novel inhibitors of the anti infective target... 171K€ Cerrado

MALARIA TARGETS ID Mapping the Targets of Antimalarial Compounds Through Chemic... 100K€ Cerrado

SIGNIA SIGNIA An innovative drug discovery platform for rapid iden... 71K€ Cerrado

Duración del proyecto: 52 meses Fecha Inicio: 2020-05-12
Fecha Fin: 2024-09-30

Líder del proyecto

HELMHOLTZZENTRUM FUR INFEKTIONSFORSCHUNG GMBH No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 3M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Anti-infective resistance is a serious global healthcare issue, calling for the development of compounds with a novel mode of action. An interdisciplinary approach will afford potent and selective inhibitors of the underexplored methylerythritol phosphate pathway, a rich source of targets that are essential for medically relevant pathogens such as the causative agents of malaria and tuberculosis. The discovery of anti-infective agents requires a highly interdisciplinary approach. A lack of a coherent training on the fundamental aspects and design principles encompassing all relevant disciplines delays the discovery and optimisation of urgently needed candidates for commercial development. This network aims to train the next generation of scientists with cutting-edge interdisciplinary skills in the discovery of new anti-infective agents through a an innovative training programme, setting the stage for the discovery of urgently needed anti-infectives with an unprecedented mechanism of action, as a springboard for translational research and industrial applications. There is a natural progression in both the training and research programme from (i) structural biology of the target enzymes, via (ii) the design and synthesis of inhibitors to (iii) fragment screening as well as multiparameter optimisation including cell-based testing and profiling with chemical proteomics. This network unites leading experts with complementary expertise in anti-infective agents from across Europe and comprises 17 partners in total: 11 academic partners and 6 non-academic partners from 8 countries, including 3 SMEs (1 designing screening libraries, 1 using chemical proteomics for target identification/deconvolution and the study of resistance formation and 1 developing bioinformatics tools for drug discovery), 1 large pharmaceutical company and 2 charities focussing on neglected diseases and promoting science to the general audience.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores